Wealth Enhancement Advisory Services, LLC Zentalis Pharmaceuticals, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $49 Billion
- Q1 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 234,071 shares of ZNTL stock, worth $353,447. This represents 0.0% of its overall portfolio holdings.
Number of Shares
234,071
Previous 200,113
16.97%
Holding current value
$353,447
Previous $606,000
38.61%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ZNTL
# of Institutions
140Shares Held
60.7MCall Options Held
7.9KPut Options Held
42.5K-
Matrix Capital Management Company, LP Waltham, MA14MShares$21.1 Million6.94% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$7.28 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.26MShares$4.92 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.07MShares$4.63 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.67MShares$4.04 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $86M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...